New treatment strategies in schizophrenia beyond dopamine: Glutamatergic neurotransmission and more

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1474-1475

  Mulert, C ^a   Scarr, E ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SECOND GENERATION ANTIPSYCHOTIC; UNCLASSIFIED DRUG; DOPAMINE; GLUTAMATE RECEPTOR;

COGNITIVE DEFECT; DOPAMINERGIC TRANSMISSION; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; HIPPOCAMPUS; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PSYCHOLOGICAL WELL BEING; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANTIPSYCHOTIC AGENTS; DOPAMINE; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 84862589733     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784871     Document Type: Editorial

References (17)

1. Möller H.-J.: Pharmacotherapy of schizophrenic patients: Achievements, unsolved needs, future research necessities. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1476-1489.
2. Karamatskos E., Mulert C., Lambert M., Naber D.: Subjective well-being of patient with schizophrenia as a target of drug treatment. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1490-1499.
3. Lisman, J.E., et al.: Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci, 2008. 31(5): p. 234-242.
4. Egerton A., Stone J.M.: The glutamate hypothesis of schizophrenia: Neuroimaging and drug development. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1500-1512.
5. Wirth C., Schubert F., Lautenschlager M., Brühl R., Klär A., Majic T., Lang U.E., Ehrlich A., Winterer G., Sander T., Schouler-Ocak M., Gallinat J.: DTNBP1 (Dysbindin) Gene Variants: In vivo evidence for effects on hippocampal glutamate status. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1513-1521.
6. Gray L.J., Hannan A.J., Zhang X.: Metabotropic glutamate receptors as targets for novel antipsychotic treatments. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1522-1534.
7. McCullumsmith R. E., Hammond J., Funk A., Meador-Woodruff J.H.: Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1535-1542.
8. Gaspar P.A., Bustamante M.L., Rojo L.E., Martinez A.: From glutamatergic dysfunction to cognitive impairment: Boundaries in the therapeutic of the schizophrenia. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1543-1548.
9. Genius J., Giegling I., Benninghoff J., Rujescu D.: Disturbed function of GABAergic interneurons in schizophrenia: Relevance for medical treatment? Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1549-1556.
10. Stan A., Lewis D. A.: Altered cortical GABA neurotransmission in schizophrenia: Insights into novel therapeutic strategies. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1557-1562.
11. Dean B.: Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1563-1571.
12. Meltzer H. Y., Massey B. W., Horiguchi M.: Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1572-1586.
13. Ibrahim H.M., Tamminga C.A.: Treatment of cognitive dysfunction in schizophrenia. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1587-1594.
14. Wobrock T., Hasan A., Falkai P.: Innovative treatment approaches in schizophrenia enhancing neuroplasticity: Aerobic exercise, erythropoetin and repetitive transcranial magnetic stimulation. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1595-1605.
15. Müller N., Schwarz M.J.: Immunological treatment options for schizophrenia. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1606-1613.
16. Rujescu D., Genius J., Benninghoff J., Giegling I.: Current progress in the genetic research of schizophrenia: Relevance for drug discovery? Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1614-1621.
17. Karch S., Pogarell O., Mulert C.: Functional Magnetic Resonance Imaging and treatment strategies in schizophrenia. Special edition of CPB, "New Treatment Strategies in Schizophrenia" Curr. Pharm. Biotechnol., (2012), 13(8), 1622-1629.